CTNM Contineum Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1855175 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-6.9%
TTM EPS YoY21.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-29.8%
ROA-28.3%
ROIC (approx.)-37.1%
Asset turnover—
Leverage & solvency
Liabilities / assets4.5%
Debt / equity0.00x
Current ratio31.11x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-5.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | — | $0 | $50.00M |
| R&D expense | $51.52M | $38.42M | $27.60M |
| SG&A expense | $16.54M | $12.47M | $6.32M |
| Operating income | -$68.06M | -$50.89M | $16.08M |
| Interest expense | — | $0 | $208,000 |
| Pretax income | -$60.14M | -$42.26M | $23.17M |
| Income tax | $0 | $0 | $450,000 |
| Net income | -$59.98M | -$42.26M | $22.72M |
| EBITDA | -$67.74M | -$50.64M | $16.27M |
| EPS (basic) | -2.17 | -2.18 | 1.36 |
| EPS (diluted) | -2.17 | -2.18 | 0.08 |
| Weighted avg. shares (diluted) | 27.70M | 19.35M | 3.40M |
| Balance sheet | |||
| Cash & equivalents | $75.60M | $21.94M | $15.53M |
| Short-term investments | $187.29M | $182.82M | $109.66M |
| Current assets | $267.92M | $206.39M | $127.71M |
| PP&E, net | $830,000 | $989,000 | $678,000 |
| Total assets | $276.64M | $212.85M | $130.39M |
| Current liabilities | $9.74M | $9.97M | $5.48M |
| Total liabilities | $15.65M | $14.78M | $5.70M |
| Shareholders' equity | $260.99M | $198.07M | -$67.94M |
| Shares outstanding | — | — | 2.35M |
| Cash flow statement | |||
| Operating cash flow | -$55.31M | -$32.84M | $19.35M |
| Capital expenditure | $231,000 | $514,000 | $414,000 |
| Free cash flow | -$55.54M | -$33.36M | $18.93M |
| Investing cash flow | -$3.71M | -$69.74M | -$65.57M |
| Financing cash flow | $112.69M | $109.00M | $56.18M |
| Depreciation & amortization | $323,000 | $258,000 | $195,000 |
| Stock-based compensation | $10.04M | $6.80M | $2.22M |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.